Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.72 |
| ▸ | MAOA | P21397 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | MIF | P14174 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471214 | 0.84 | ALDH1A1 (1.00) | MAOBMAOAALDH1A1MIFHPGD | |
| SCHEMBL11319226 | 0.84 | MAOA (1.00) | MAOBMAOAALDH1A1MIFHPGD | |
| SCHEMBL51507 | 0.83 | MAOB (0.73) | MAOBMAOAALDH1A1MIFHPGD | |
| SCHEMBL6832346 | 0.82 | MAOB (0.76) | MAOBMAOAALDH1A1MIFHPGD | |
| SCHEMBL980268 | 0.80 | GPR35 (0.76) | MAOBMAOAALDH1A1KDM4EGPR35 | |
| SCHEMBL29628919 | 0.80 | GPR35 (0.76) | MAOBMAOAALDH1A1KDM4EGPR35 | |
| SCHEMBL1711081 | 0.79 | MAOB (0.72) | MAOBMAOAALDH1A1MIFHPGD | |
| SCHEMBL2038036 | 0.79 | MAOA (0.72) | MAOBMAOAALDH1A1MIFHPGD | |
| SCHEMBL52086 | 0.79 | MAOB (0.72) | MAOBMAOAALDH1A1MIFHPGD | |
| SCHEMBL20079506 | 0.79 | ALDH1A1 (0.72) | MAOBMAOAALDH1A1MIFHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951870-B2 | Coumarin derivatives with COMT inhibiting activity | ORION CORPORATION (FI) | 2005-10-04 | — | — | US | disclosed |
| US-20040110750-A9 | Coumarin derivatives with comt inhibiting activity | ORION CORPORATION (FI) | 2004-06-10 | — | — | US | disclosed |
| EP-1301503-B1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORP (FI) | 2004-02-25 | — | — | EP | disclosed |
| US-20030186975-A1 | Coumarin derivatives with comt inhibiting activity | PYSTYNEN JARMO (FI) | 2003-10-02 | — | — | US | disclosed |
| EP-1301503-A1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002002548-A1 | COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY | ORION CORPORATION (FI) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110750-A9 | Coumarin derivatives with comt inhibiting activity | COMT, CYP1A1, CYP2D6 | MAOB 58/4885MAOA 53/4885ALDH1A1 85/4885 |
| US-20030186975-A1 | Coumarin derivatives with comt inhibiting activity | COMT, CYP1A1, CYP2D6 | MAOB 58/4885MAOA 53/4885ALDH1A1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.